Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Six Pharma CEOs To Testify In House as Democrats, Trump Compete For Attention On Drug Pricing

Executive Summary

While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere. 

You may also be interested in...



Revlimid And Copaxone Pricing: Five Not-So-Revealing Revelations From The House Reports

Investigative reports from the House Oversight and Reform Committee recount well-known records of significant price increases for the drugs, the lack of pricing restraints in the US relative to markets abroad, tactics used to protect the drugs from generic competition and the 'return on investment' from manufacturer assistance programs.

US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches

Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.

US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches

Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel